Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Lonza Biotec

Order year

March 2003


Visp, Switzerland

Estimated investment

CHF100m + CHF30m; CHF80m for API plant; CHF24m for cytotoxicfacility expansion


Late 2003 and mid 2006; API plant 2010; cytotoxic plant 2012

Output chemicals

Recombinant proteins, monoclonal antibodies, APIs


Lonza Biotec, Lonza Ltd, Lonza Exclusive Synthesis

Contractors and suppliers

BBS Systems, Aerni Ag, Orbimatic

Project management

Lonza Group

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top